Plant Comparison
Astragalus vs Perforate St John’s-wort
A side-by-side comparison of two medicinal plants — every documented constituent, action, use, safety note and cited source, assembled automatically from the Omnia Sana database.
At a glance
Astragalus and Perforate St John’s-wort: they share 5 indicated uses (arthritis / joint pain, cold & flu, infection (general), …); 2 pharmacological actions in common.
Evidence face-off — shared uses
| Condition | Astragalus | Perforate St John’s-wort | Verdict |
|---|---|---|---|
| Arthritis / joint pain | 1/10 | 1/10 | Comparable evidence |
| Cold & flu | 2/10 | 1/10 | Comparable evidence |
| Infection (general) | 2/10 | 1/10 | Comparable evidence |
| Inflammation (general) | 1/10 | 1/10 | Comparable evidence |
| Skin irritation | 1/10 | 1/10 | Comparable evidence |
Evidence scores (1–10) are computed from the tier of each cited source. “Comparable” means the two scores are within one point. Follow a score to its detailed sources.
Key Constituents
Major bioactive saponin with cardio-, neuro-, hepato- and renoprotective effects.
Red pigments historically used to standardise extracts; contribute to antiviral activity and are the compounds responsible for photosensitivity risk.
Considered the principal compound behind the antidepressant activity and the main driver of the herb's potent CYP3A4/P-glycoprotein induction and drug-interaction profile.
Antioxidant flavonoids contributing to overall activity.
Pharmacological Actions
Astragalus membranaceus and its constituents (astragaloside IV, cycloastragenol, Astragalus polysaccharide) inhibit tumour growth, invasion and metastasis and enhance antitumour immunity across lung, colorectal and gastrointestinal cancers (preclinical, incl. in vivo).
Immune support / immunomodulation (activates macrophages, NK cells, T and B lymphocytes)
Traditional & Indicated Uses
inferred from anti-inflammatory action
Astragalus membranaceus protects against gastrointestinal cancers; astragaloside IV inhibits lung cancer metastasis via macrophage repolarization, cycloastragenol boosts CD8+ T-cell antitumour immunity (with anti-PD-1 synergy), and Astragalus polysaccharide suppresses inflammation-induced colorectal cancer (preclinical).
Supports resistance to colds and respiratory infection (immune)
Adaptogenic tonic for fatigue and low vitality (traditional 'Qi' tonic)
Immune support / immunomodulation (activates macrophages, NK cells, T and B lymphocytes); Supports resistance to colds and respiratory infection (immune)
Supports resistance to colds and respiratory infection (immune)
inferred from anti-inflammatory action
Renoprotective (kidney support) - as an adjunct in chronic kidney disease, reduced proteinuria and raised haemoglobin and serum albumin across trials (Cochrane review; study quality low)
inferred from anti-inflammatory action
inferred from anti-inflammatory action
inferred from antiviral action
inferred from anti-inflammatory action
inferred from sedative action
inferred from anti-inflammatory action
Safety, Cautions & Contraindications
Astragalus stimulates immune activity; on theoretical grounds it should be used cautiously in autoimmune disease and with immunosuppressant medicines (for example after organ transplant) - discuss with a clinician.
Generally well tolerated; high-quality long-term human safety and toxicity data remain limited.
Safety in pregnancy and breastfeeding has not been established; avoid medicinal doses.
Significant drug interactions: strongly induces CYP3A4 and P-glycoprotein, reducing plasma levels of many drugs including oral contraceptives, antiretrovirals, cyclosporine, warfarin, and digoxin. May cause photosensitivity (fair-skinned individuals). Do not combine with SSRIs, SNRIs, or MAOIs (serotonin syndrome risk). Avoid in bipolar disorder.
Duke (2002) rates St. John's wort as ++ (raised from earlier editions) and notes antidepressant, antiviral, antibacterial, and wound-healing activities at experimental and clinical levels. Hypericin and hyperforin are identified as key active constituents. Clinical evidence (score 2) confirms antidepressant efficacy in mild-to-moderate depression, and WHO/Commission E provide approval for this indication. Dose: 300 mg standardized extract (0.3% hypericin, 3–5% hyperforin) three times daily. Duke emphasizes the critical drug interaction: St. John's wort is a potent CYP3A4 inducer and can significantly reduce blood levels of many medications including oral contraceptives, cyclosporine, antiretrovirals, and warfarin. Avoid combined use with SSRIs (serotonin syndrome risk) and pharmaceutical antidepressants (Duke, 2002).
External Ids
Botanical Description
Erect perennial herb with a long, fibrous, pale yellow taproot. The leaves are pinnately compound with numerous small, oval leaflets, giving a soft, ferny appearance. Small, pale yellow, pea-like flowers are borne in loose axillary clusters (racemes), followed by membranous, inflated seed pods that give the species its name.[5]
Erect, branching perennial herb with paired, oval leaves dotted with tiny translucent oil glands that look like pinpricks when held to the light (giving the species name 'perforatum'). Bright yellow, five-petalled flowers with numerous stamens and black dots along the petal edges are borne in flat-topped clusters, and release a reddish pigment when crushed.[4]
Habitat
Native to the grasslands, sunny slopes and forest margins of northern and north-eastern China, Mongolia and parts of Korea; widely cultivated as a medicinal crop across East Asia.[5]
Grows in grassland, roadsides, woodland clearings and waste ground on well-drained soils; native to Europe, Western Asia and North Africa and widely naturalised elsewhere, including North America and Australia.[4]
Harvesting
The root is dug from plants at least four years old, typically in spring or autumn, then cleaned and dried, often sliced into the characteristic pale, fibrous 'coin' slices used in traditional decoctions.[5]
The flowering tops (flower and upper leaf) are cut in summer as the flowers open, around the traditional St John's Day period, and dried quickly in a warm, shaded, airy place to preserve the hypericin and hyperforin content.[4]
Traditional Uses
St John's wort has a centuries-long European folk reputation as a wound-healing and nerve tonic herb, traditionally used for mild wounds, burns and nerve pain and to lift low mood; this traditional mood-supporting use is now one of the most extensively clinically studied applications of any herbal medicine, with standardised extracts shown comparable to conventional antidepressants for mild-to-moderate depression.[1, 4]
Preparations
Flowering-top extract standardised to hypericin and/or hyperforin content, taken as tablets or capsules; the best-studied clinical form for mood support.
Dosage
The WHO monograph on Radix Astragali gives doses of 3-9 g per day. Traditional Chinese medicine references often cite a considerably higher 9-30 g of dried root per day; WHO's figure is the conservative regulatory-tier one and is stated here in preference. Educational reference only, not a prescription.
Clinical studies commonly use extracts providing the equivalent of several grams of dried root daily, in divided doses. Educational reference only, not a prescription.
Clinical trials for mild-to-moderate depression commonly use around 300 mg of standardised extract three times daily (900 mg/day total); given extensive drug interactions, use should be discussed with a healthcare provider, especially alongside other medicines. Educational reference only, not a prescription.
References
Lookalikes Review
Drug Class Interactions
Not documented
Pairings
Not documented
St John's wort raises serotonin activity and can cause serotonin syndrome when combined with other serotonin-boosting agents; pairing it with another mood-active, serotonergic herb such as saffron may add to this risk.[30]
St John's wort is a strong enzyme inducer and increases serotonin activity; combining it with another antidepressant-type herb such as rhodiola may add to serotonergic effects and unpredictably change how each is handled by the body.[30]
St John's wort speeds up the breakdown of many substances and also raises serotonin activity; pairing it with a sedative herb such as valerian may add to drowsiness and can unpredictably change how each is handled by the body.[30, 31]
St John's wort is a strong enzyme inducer and kava is a liver-metabolised sedative; combining them may add to central-nervous-system effects and alter how kava is processed, so combined use warrants caution.[30, 31]
References & Sources
- Xu, B., Huang, J.P., Peng, G., Cao, W., Liu, Z. et al (2024) 'Total biosynthesis of the medicinal triterpenoid saponin astragalosides', Nature Plants, 10(11), pp. 1826-1837. doi:10.1038/s41477-024-01827-4 Preclinical
https://doi.org/10.1038/s41477-024-01827-4 - Auyeung, K.K., Han, Q.B. and Ko, J.K (2016) 'Astragalus membranaceus: A Review of its Protection Against Inflammation and Gastrointestinal Cancers', The American Journal of Chinese Medicine, 44(1), pp. 1-22. doi:10.1142/S0192415X16500014 Traditional / reference
https://doi.org/10.1142/S0192415X16500014 - Zhang, Y., Ji, W., Qin, H., Chen, Z., Zhou, Y. et al (2024) 'Astragalus polysaccharides alleviate DSS-induced ulcerative colitis in mice by restoring SCFA production and regulating Th17/Treg cell homeostasis in a microbiota-dependent manner', Carbohydrate Polymers, 349, pp. 122829. doi:10.1016/j.carbpol.2024.122829 Preclinical
https://doi.org/10.1016/j.carbpol.2024.122829 - Fu, J., Wang, Z., Huang, L., Zheng, S., Wang, D., Chen, S., Zhang, H. and Yang, S (2014) 'Review of the botanical characteristics, phytochemistry, and pharmacology of Astragalus membranaceus (Huangqi)', Phytotherapy Research, 28(9), pp. 1275-1283. doi:10.1002/ptr.5188 Meta-analysis / review
https://doi.org/10.1002/ptr.5188 - Zhang, J., Wu, C., Gao, L., Du, G. and Qin, X (2019) 'Astragaloside IV derived from Astragalus membranaceus: A research review on the pharmacological effects', Advances in Pharmacology. doi:10.1016/bs.apha.2019.08.002 Traditional / reference
https://doi.org/10.1016/bs.apha.2019.08.002 - Dong, M., Li, J., Yang, D., Li, M. and Wei, J (2023) 'Biosynthesis and pharmacological activities of flavonoids, triterpene saponins and polysaccharides derived from Astragalus membranaceus', Molecules, 28(13), pp. 5018. doi:10.3390/molecules28135018 Meta-analysis / review
https://doi.org/10.3390/molecules28135018 - Chen, G., Jiang, N., Zheng, J., Hu, H., Yang, H., Lin, A., Hu, B. and Liu, H (2023) 'Structural characterization and anti-inflammatory activity of polysaccharides from Astragalus membranaceus', International Journal of Biological Macromolecules, 241, pp. 124386. doi:10.1016/j.ijbiomac.2023.124386 Preclinical
https://doi.org/10.1016/j.ijbiomac.2023.124386 - Zheng, Q., Zhuang, Z., Wang, Z., Deng, L., Jin, W., Huang, Z., Zheng, G. and Wang, Y (2020) 'Clinical and preclinical systematic review of Astragalus membranaceus for viral myocarditis', Oxidative Medicine and Cellular Longevity, 2020, pp. 1560353. doi:10.1155/2020/1560353 Meta-analysis / review
https://doi.org/10.1155/2020/1560353 - Dai, Y., Wang, Y., Kang, Q., Wu, Y., Liu, Y., Su, Y., Wang, X., Xiu, M. and He, J (2024) 'The protective effect and bioactive compounds of Astragalus membranaceus against neurodegenerative disorders via alleviating oxidative stress in Drosophila', FASEB Journal, 38(13), pp. e23727. doi:10.1096/fj.202400390R Preclinical
https://doi.org/10.1096/fj.202400390R - Xu, L., Xu, X., Hou, X., Wang, F., Gao, S. and Zhang, H (2019) 'Adjuvant therapy with Astragalus membranaceus for post-stroke fatigue: a systematic review', Metabolic Brain Disease, 35(1), pp. 83-93. doi:10.1007/s11011-019-00483-4 Meta-analysis / review
https://doi.org/10.1007/s11011-019-00483-4 - Li, C.X., Liu, Y., Zhang, Y.Z., Li, J.C. and Lai, J (2022) 'Astragalus polysaccharide: a review of its immunomodulatory effect', Archives of Pharmacal Research. doi:10.1007/s12272-022-01393-3 Preclinical
https://doi.org/10.1007/s12272-022-01393-3 - Jin, M., Zhao, K., Huang, Q. and Shang, P (2014) 'Structural features and biological activities of the polysaccharides from Astragalus membranaceus', International Journal of Biological Macromolecules, 64, pp. 257-266. doi:10.1016/j.ijbiomac.2013.12.002 Preclinical
https://doi.org/10.1016/j.ijbiomac.2013.12.002 - Liu, Y. and Lv, W (2019) 'Research progress in Astragalus membranaceus and its active components on immune responses in liver fibrosis', Chinese Journal of Integrative Medicine, 26(10), pp. 794-800. doi:10.1007/s11655-019-3039-1 Meta-analysis / review
https://doi.org/10.1007/s11655-019-3039-1 - World Health Organization (1999) 'Radix Astragali'. Available at: https://iris.who.int/items/6418d8af-5200-4e6b-9bf5-004f3aa62a37 Traditional / reference
https://iris.who.int/items/6418d8af-5200-4e6b-9bf5-004f3aa62a37 - Xu, F. and Cui, W.-Q. and Wei, Y. and Cui, J. and Qiu, J. and Hu, L.-L. and Gong, W.-Y. and Dong, J.-C. and Liu, B.-J (2018) 'Astragaloside IV inhibits lung cancer progression and metastasis by modulating macrophage polarization through AMPK signaling', Journal of Experimental & Clinical Cancer Research, 37(1), pp. 207. doi:10.1186/s13046-018-0878-0 Preclinical
https://doi.org/10.1186/s13046-018-0878-0 - Deng, G. and Zhou, L. and Wang, B. and Sun, X. and Zhang, Q. and Chen, H. and Wan, N. and Ye, H. and Wu, X. and Sun, D. and Sun, Y. and Cheng, H (2022) 'Targeting cathepsin B by cycloastragenol enhances antitumor immunity of CD8 T cells via inhibiting MHC-I degradation', Journal for ImmunoTherapy of Cancer, 10(10), pp. e004874. doi:10.1136/jitc-2022-004874 Preclinical
https://doi.org/10.1136/jitc-2022-004874 - Li, Q. and Zhang, C. and Xu, G. and Shang, X. and Nan, X. and Li, Y. and Liu, J. and Hong, Y. and Wang, Q. and Peng, G (2024) 'Astragalus polysaccharide ameliorates CD8 T cell dysfunction through STAT3/Gal-3/LAG3 pathway in inflammation-induced colorectal cancer', Biomedicine & Pharmacotherapy, 171, pp. 116172. doi:10.1016/j.biopha.2024.116172 Preclinical
https://doi.org/10.1016/j.biopha.2024.116172 - Zhang, H.W., Lin, Z.X., Xu, C., Leung, C. and Chan, L.S (2014) 'Astragalus (a traditional Chinese medicine) for treating chronic kidney disease', Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD008369.pub2 Meta-analysis / review
https://doi.org/10.1002/14651858.CD008369.pub2
- Ng, Q.X., Venkatanarayanan, N. and Ho, C.Y.X (2017) 'Clinical use of Hypericum perforatum (St John's wort) in depression: A meta-analysis', Journal of Affective Disorders, 210, pp. 211-221. doi:10.1016/j.jad.2016.12.048 Meta-analysis / review
https://doi.org/10.1016/j.jad.2016.12.048 - Kholghi, G., Arjmandi-Rad, S., Zarrindast, M.R. and Vaseghi, S (2022) 'St. John's wort (Hypericum perforatum) and depression: what happens to the neurotransmitter systems?', Naunyn-Schmiedeberg's Archives of Pharmacology, 395(6), pp. 629-642. doi:10.1007/s00210-022-02229-z Traditional / reference
https://doi.org/10.1007/s00210-022-02229-z - Fugh-Berman, A (2000) 'Herb-drug interactions', Lancet, 355(9198), pp. 134-138. doi:10.1016/S0140-6736(99)06457-0 Traditional / reference
https://doi.org/10.1016/S0140-6736(99)06457-0 - Nobakht, S.Z., Akaberi, M., Mohammadpour, A.H., Tafazoli Moghadam, A. and Emami, S.A (2022) 'Hypericum perforatum: Traditional uses, clinical trials, and drug interactions', Iranian Journal of Basic Medical Sciences, 25(9), pp. 1045-1058. doi:10.22038/IJBMS.2022.65112.14338 Meta-analysis / review
https://doi.org/10.22038/IJBMS.2022.65112.14338 - Jiang, Z., Wang, F., Zhao, Y., Lu, L., Jiang, X., Huang, T., Lin, Y., Guo, L., Weng, Z. and Liu, E (2024) 'Hypericum perforatum L. attenuates depression by regulating Akkermansia muciniphila, tryptophan metabolism and NFkB-NLRP2-Caspase1-IL1beta pathway', Phytomedicine, 132, pp. 155847. doi:10.1016/j.phymed.2024.155847 Preclinical
https://doi.org/10.1016/j.phymed.2024.155847 - Oliveira, A.I., Pinho, C., Sarmento, B. and Dias, A.C.P (2016) 'Neuroprotective Activity of Hypericum perforatum and Its Major Components', Frontiers in Plant Science, 7, pp. 1004. doi:10.3389/fpls.2016.01004 Meta-analysis / review
https://doi.org/10.3389/fpls.2016.01004 - Russo, E., Scicchitano, F., Whalley, B.J., Mazzitello, C., Ciriaco, M., Esposito, S., Patane, M., Upton, R., Pugliese, M., Chimirri, S., Mammi, M., Palleria, C. and De Sarro, G (2013) 'Hypericum perforatum: pharmacokinetic, mechanism of action, tolerability, and clinical drug-drug interactions', Phytotherapy Research, 28(5), pp. 643-655. doi:10.1002/ptr.5050 Meta-analysis / review
https://doi.org/10.1002/ptr.5050 - Saddiqe, Z., Naeem, I. and Maimoona, A (2010) 'A review of the antibacterial activity of Hypericum perforatum L', Journal of Ethnopharmacology, 131(3), pp. 511-521. doi:10.1016/j.jep.2010.07.034 Meta-analysis / review
https://doi.org/10.1016/j.jep.2010.07.034 - Mennini, T. and Gobbi, M (2004) 'The antidepressant mechanism of Hypericum perforatum', Life Sciences, 75(9), pp. 1021-1027. doi:10.1016/j.lfs.2004.04.005 Meta-analysis / review
https://doi.org/10.1016/j.lfs.2004.04.005 - Liu, Y., Jiang, Y., Huang, R., Yang, J., Xiao, B. and Dong, J (2013) 'Hypericum perforatum L. preparations for menopause: a meta-analysis of efficacy and safety', Climacteric, 17(4), pp. 325-335. doi:10.3109/13697137.2013.861814 Meta-analysis / review
https://doi.org/10.3109/13697137.2013.861814 - Wurglics, M. and Schubert-Zsilavecz, M (2006) 'Hypericum perforatum: a 'modern' herbal antidepressant: pharmacokinetics of active ingredients', Clinical Pharmacokinetics, 45(5), pp. 449-468. doi:10.2165/00003088-200645050-00002 Meta-analysis / review
https://doi.org/10.2165/00003088-200645050-00002 - Kasper, S (2001) 'Hypericum perforatum - a review of clinical studies', Pharmacopsychiatry, 34(Suppl 1), pp. S51-S55. doi:10.1055/s-2001-15467 Meta-analysis / review
https://doi.org/10.1055/s-2001-15467 - Nathan, P (1999) 'The experimental and clinical pharmacology of St John's Wort (Hypericum perforatum L.)', Molecular Psychiatry, 4(4), pp. 333-338. doi:10.1038/sj.mp.4000557 Meta-analysis / review
https://doi.org/10.1038/sj.mp.4000557 - Verotta, L (2003) 'Hypericum perforatum, a source of neuroactive lead structures', Current Topics in Medicinal Chemistry, 3(2), pp. 187-201. doi:10.2174/1568026033392589 Meta-analysis / review
https://doi.org/10.2174/1568026033392589 - Linde, K. et al (2008) 'St John'. Traditional / reference
https://scholar.google.com/scholar?q=St%20John - Natural Standard (2013) 'Hypericum perforatum (St'. Traditional / reference
https://scholar.google.com/scholar?q=Hypericum%20perforatum%20%28St - Duke, J.A (2002) 'Handbook of Medicinal Herbs, Second Edition'. Traditional / reference
https://scholar.google.com/scholar?q=Handbook%20of%20Medicinal%20Herbs%2C%20Second%20Edition - Zhou, S., Chan, E., Pan, S.Q., Huang, M. and Lee, E.J.D (2004) 'Pharmacokinetic interactions of drugs with St John's wort', Journal of Psychopharmacology, 18(2), pp. 262-276. doi:10.1177/0269881104042632 Meta-analysis / review
https://doi.org/10.1177/0269881104042632 - Izzo, A.A. and Ernst, E (2009) 'Interactions between herbal medicines and prescribed drugs: an updated systematic review', Drugs, 69(13), pp. 1777-1798. doi:10.2165/11317010-000000000-00000 Meta-analysis / review
https://doi.org/10.2165/11317010-000000000-00000 - Borrelli, F. and Izzo, A.A (2009) 'Herb-drug interactions with St John's wort (Hypericum perforatum): an update on clinical observations', The AAPS Journal, 11(4), pp. 710-727. doi:10.1208/s12248-009-9146-8 Meta-analysis / review
https://doi.org/10.1208/s12248-009-9146-8 - Nicolussi, S., Drewe, J., Butterweck, V. and Meyer zu Schwabedissen, H.E (2020) 'Clinical relevance of St. John's wort drug interactions revisited', British Journal of Pharmacology, 177(6), pp. 1212-1226. doi:10.1111/bph.14936 Meta-analysis / review
https://doi.org/10.1111/bph.14936 - Piscitelli, S.C., Burstein, A.H., Chaitt, D., Alfaro, R.M. and Falloon, J (2000) 'Indinavir concentrations and St John's wort', Lancet, 355(9203), pp. 547-548. doi:10.1016/S0140-6736(99)05712-8 Clinical study
https://doi.org/10.1016/S0140-6736(99)05712-8 - Barone, G.W., Gurley, B.J., Ketel, B.L., Lightfoot, M.L. and Abul-Ezz, S.R (2000) 'Drug interaction between St. John's wort and cyclosporine', Annals of Pharmacotherapy, 34(9), pp. 1013-1016. doi:10.1345/aph.10088 Clinical study
https://doi.org/10.1345/aph.10088 - Murphy, P.A., Kern, S.E., Stanczyk, F.Z. and Westhoff, C.L (2005) 'Interaction of St. John's Wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding', Contraception, 71(6), pp. 402-408. doi:10.1016/j.contraception.2004.11.004 Clinical study
https://doi.org/10.1016/j.contraception.2004.11.004 - Murphy, P.A., Kern, S.E., Stanczyk, F.Z. and Westhoff, C.L (2005) 'Interaction of St. John's Wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding', Contraception, 71(6), pp. 402-408. doi:10.1016/j.contraception.2004.11.004 Clinical study
https://doi.org/10.1016/j.contraception.2004.11.004 - Pfrunder, A., Schiesser, M., Gerber, S., Haschke, M., Bitzer, J. and Drewe, J (2003) 'Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial', British Journal of Clinical Pharmacology, 56(6), pp. 683-690. doi:10.1046/j.1365-2125.2003.02005.x Randomized trial
https://doi.org/10.1046/j.1365-2125.2003.02005.x - Johne, A., Brockmoller, J., Bauer, S., Maurer, A., Langheinrich, M. and Roots, I (1999) 'Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum)', Clinical Pharmacology and Therapeutics, 66(4), pp. 338-345. doi:10.1053/cp.1999.v66.a101944 Clinical study
https://doi.org/10.1053/cp.1999.v66.a101944 - Mathijssen, R.H.J., Verweij, J., de Bruijn, P., Loos, W.J. and Sparreboom, A (2002) 'Effects of St. John's wort on irinotecan metabolism', Journal of the National Cancer Institute, 94(16), pp. 1247-1249. doi:10.1093/jnci/94.16.1247 Randomized trial
https://doi.org/10.1093/jnci/94.16.1247 - Smith, P., Bullock, J.M., Booker, B.M., Haas, C.E., Berenson, C.S. and Jusko, W.J (2004) 'The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate', Pharmacotherapy, 24(11), pp. 1508-1514. doi:10.1592/phco.24.16.1508.50958 Clinical study
https://doi.org/10.1592/phco.24.16.1508.50958 - Izzo, A.A (2004) 'Drug interactions with St. John's Wort (Hypericum perforatum): a review of the clinical evidence', International Journal of Clinical Pharmacology and Therapeutics, 42(3), pp. 139-148. doi:10.5414/cpp42139 Meta-analysis / review
https://doi.org/10.5414/cpp42139 - Caus, M.N., Lupoae, M. and Chitescu, C.L (2026) 'Efficacy and Safety of Herbal Supplements with Anxiolytic, Antidepressant, and Sedative Action: A Review of Clinical Data and Toxicological Risks', Pharmaceuticals, 19(3), pp. 399. doi:10.3390/ph19030399 Meta-analysis / review
https://doi.org/10.3390/ph19030399
Generated automatically from the Omnia Sana plant database and its cited sources. For educational purposes only — not medical advice. Always consult a qualified practitioner before using medicinal plants.